CA-HAI-ROBOTICS
31.3.2023 04:27:24 CEST | Business Wire | Press release
Hai Robotics, a leading provider of intelligent automated warehousing solutions, has won the MHI Innovation Award for Best Innovation of an Existing Product for their A42T Autonomous Case-handling Robot (ACR). This prestigious award was announced at ProMat 2023, held in Chicago, on Wednesday, March 22nd.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230327005769/en/
The MHI Innovation Award recognizes Hai Robotics for their groundbreaking work in developing advanced equipment for automated storage and retrieval solutions (ASRS) and recognizes the company's commitment to advancing their customer’s success with innovative and cutting-edge technology.
The A42T ACR is the first goods-to-person equipment that extends upward allowing facilities to store items up to 10m (32+ feet) high, while remaining independent of any storage medium. It is highly intelligent, able to handle most totes or container sizes and types, even cardboard boxes, on standard industry shelving structures. Comparable systems often require unique and expensive custom precision structures with limited tote options to function, but the A42T ACR is a revolutionary robotic design, freeing facilities of the old rigid ASRS constructs. This robot provides maximum system flexibility typically seen with AMR or AGV technology while allowing facilities to obtain modern warehouse density with maximum use of vertical storage.
This award is a testament to Hai Robotics’ dedication to excellence and its ability to deliver intelligent automation solutions that help businesses increase efficiency, reduce costs, reduce storage footprint, and improve overall productivity.
"We are thrilled to have won the Innovation Award at ProMat 2023," said Brian Zheng, CEO of Hai Robotics USA. "This award is a recognition of our team's hard work, dedication, and commitment to driving innovation in the industry. We are proud to be at the forefront of intelligent warehouse automation and are committed to delivering advanced solutions that help our customers stay ahead of the game."
The ProMat 2023 event brought together many thousands of industry experts, professionals, and businesses from around the world to showcase the latest technologies, products, and solutions in the field of automation and material handling. The event is an excellent opportunity for attendees to explore new technologies. Visitors were able to witness the A42T ACR live where it demonstrated 32-foot-high tote picks from one of the tallest structures built at the event.
"We are honored to have received this prestigious award, and we thank MHI for hosting such an exceptional event," said Rebecca Lennartz, Director of Marketing for Hai Robotics USA. "We look forward to continuing to drive innovation in the industry and helping businesses achieve their automation goals."
About HAI Robotics
Hai Robotics is a leading global provider of intelligent automated storage and retrieval systems (ASRS). Their ASRS solutions provide modern storage density, reducing their customer’s storage footprints up to 75%, increasing workflow efficiency gains up to 4x, maximizing order pick accuracy to 99.9+%, and improving daily orders fulfilled rate over 170%.
Their Autonomous Case-handling Robots (ACR) are the key equipment in their systems. These robots maximize the use of vertical space, managing the storage of goods 32+ feet high. Their solutions are independent of any storage medium so the ASRS can be built using almost any standard racking structure, and the equipment manages most kinds and sizes of bins, trays, cardboard cartons, and a variety of containers and materials.
Hai Robotics provides intelligent ASRS solutions made for real world applications.
To know more about Hai Robotics and their A42T ACR, visit their website at https://www.hairobotics.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230327005769/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release
The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom